An in-vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. 

This test uses US CDC developed technology and is designed for surveillance purposes such as estimating HIV-1 incidence in a population, monitoring and evaluating HIV intervention programs, and recognizing those high-incidence populations so that prevention research, vaccine trials, and resources are most appropriately utilized.

This product is for research use only and is not intended for use in diagnostic procedures.